Bristol Myers Squibb And Janssen Announce Milvexian Has Been Granted US FDA Fast Track Designation For All Three Indications Under Evaluation In Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome And Atrial Fibrillation
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb and Janssen announce that their drug Milvexian has been granted US FDA Fast Track Designation for all three indications under evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome, and Atrial Fibrillation.
May 25, 2023 | 10:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Milvexian receives FDA Fast Track Designation for three indications in Phase 3 Librexia Program.
The FDA Fast Track Designation for Milvexian is a positive development for Bristol Myers Squibb, as it may expedite the drug's approval process and potentially lead to increased revenues. This news is likely to have a positive short-term impact on BMY's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 50
POSITIVE IMPACT
Janssen's Milvexian, in collaboration with Bristol Myers Squibb, receives FDA Fast Track Designation for three indications in Phase 3 Librexia Program.
The FDA Fast Track Designation for Milvexian is a positive development for Janssen, a subsidiary of Johnson & Johnson, as it may expedite the drug's approval process and potentially lead to increased revenues. This news is likely to have a positive short-term impact on JNJ's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 50